Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings Analysis

Rapport Therapeutics, Inc. Common Stock (RAPP) next reports earnings on 2026-08-06, consensus EPS -0.97128 USD. Last quarter (2026-05-07) it beat with EPS -0.42 USD vs -0.56 USD est (+25%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -15.90.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RAPP next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.97128 USD
Revenue estimate0.00B

RAPP earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.42 USD-0.56 USD+25%Beat
2026-03-10-0.72 USD-0.65 USD-10.8%Miss
2025-11-06-0.71 USD-0.77 USD+7.8%Beat
2025-08-07-0.75 USD-0.87 USD+13.8%Beat
2025-03-11-0.57 USD-0.62 USD+8.1%Beat
2024-11-07-0.5 USD-0.57 USD+12.3%Beat

Beat rate: 5/6 (83%) over reported quarters with consensus data.

RAPP valuation and analyst view

Trailing P/E-15.90
Trailing EPS-2.27106 USD
Price / book4.14
Dividend yield0.00%
Market cap1.50B
Analyst consensusBuy (5 buy / 0 hold / 0 sell)
Avg price target57.67 USD

Related research pages

Frequently asked questions

When is Rapport Therapeutics, Inc. Common Stock (RAPP)'s next earnings date?

Rapport Therapeutics, Inc. Common Stock is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.97128 USD and revenue estimate of 0.00B.

Did RAPP beat earnings last quarter?

In its 2026-05-07 report, RAPP posted EPS of -0.42 USD versus a -0.56 USD estimate — a beat of 25%.

What is RAPP's earnings track record?

Over the last 6 reported quarters with consensus data, RAPP beat estimates 5 times (83%).

What is RAPP's current P/E ratio and EPS?

RAPP trades at a trailing P/E of -15.90 on trailing EPS of -2.271055899895289 USD.

What do analysts rate RAPP?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 57.67 USD.